Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 19/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.44 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14811271 | 1.00 | MTOR (0.50) | MTORPIK3CAPIK3R1ATR | |
| SCHEMBL14811270 | 1.00 | MTOR (0.50) | MTORPIK3CAPIK3R1ATR | |
| SCHEMBL20692837 | 0.97 | MTOR (0.53) | MTORPIK3CAPIK3R1 | |
| SCHEMBL21029958 | 0.97 | MTOR (0.53) | MTORPIK3CAPIK3R1 | |
| SCHEMBL21394004 | 0.97 | MTOR (0.53) | MTORPIK3CAPIK3R1 | |
| SCHEMBL19629401 | 0.97 | MTOR (0.53) | MTORPIK3CAPIK3R1 | |
| SCHEMBL22759099 | 0.91 | MTOR (0.46) | MTORPIK3CAPIK3R1 | |
| SCHEMBL23505802 | 0.89 | MTOR (0.52) | MTORPIK3CAPIK3R1 | |
| SCHEMBL21375707 | 0.89 | MTOR (0.52) | MTORPIK3CAPIK3R1 | |
| SCHEMBL20692832 | 0.89 | MTOR (0.52) | MTORPIK3CAPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212160-A1 | 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230014057-A1 | TREATMENT OF SKIN DISORDERS | TORQUR AG (CH) | 2023-01-19 | — | — | US | disclosed |
| US-20220153752-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | TORQUR AG (CH) | 2022-05-19 | — | — | US | disclosed |
| US-20220135551-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | PIQUR THERAPEUTICS AG (CH) | 2022-05-05 | — | — | US | disclosed |
| US-11186591-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | UNIVERSITÄT BASEL (CH) | 2021-11-30 | — | — | US | disclosed |
| US-20210361665-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2021-11-25 | — | — | US | disclosed |
| US-10993947-B2 | Treatment of skin lesions | TORQUR (CH) | 2021-05-04 | — | — | US | disclosed |
| US-20210107913-A1 | TREATMENT OF SKIN DISORDERS | TORQUR AG (CH) | 2021-04-15 | — | — | US | disclosed |
| WO-2020244613-A1 | 2, 4, 6-TRI-SUBSTITUTED PYRIMIDINE COMPOUND AS ATR KINASE INHIBITOR | 北京泰德制药股份有限公司 | 2020-12-10 | — | — | WO | disclosed |
| US-20200277304-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | TORQUR AG (CH) | 2020-09-03 | — | — | US | disclosed |
| US-10640516-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | PIQUR THERAPEUTICS AG (CH) | 2020-05-05 | — | — | US | disclosed |
| US-20190290653-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2019-09-26 | — | — | US | disclosed |
| US-20190284178-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | TORQUR AG (CH) | 2019-09-19 | — | — | US | disclosed |
| US-20190031682-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | TORQUR AG (CH) | 2019-01-31 | — | — | US | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361665-A1 | TREATMENT OF SKIN LESIONS | CXCR3, C3AR1, CCR3 | MTOR 4061/4885PIK3CA 3770/4885PIK3R1 3165/4885 |
| US-20220153752-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | PIK3CA, MTOR, PIKFYVE | MTOR 2/4885PIK3CA 1/4885PIK3R1 30/4885 |
| US-20210107913-A1 | TREATMENT OF SKIN DISORDERS | RXFP3, CBR3, CXCR3 | MTOR 2897/4885PIK3CA 3974/4885PIK3R1 1902/4885 |
| US-20220135551-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | CHRM1, CHRM2, C1R | MTOR 4473/4885PIK3CA 4513/4885PIK3R1 3948/4885 |
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | MTOR 155/4885PIK3CA 28/4885PIK3R1 6/4885 |
| US-10993947-B2 | Treatment of skin lesions | CXCR3, CCR3, C3AR1 | MTOR 4107/4885PIK3CA 3971/4885PIK3R1 3358/4885 |
| US-20230014057-A1 | TREATMENT OF SKIN DISORDERS | RXFP3, CCR3, CBR3 | MTOR 3212/4885PIK3CA 4158/4885PIK3R1 2100/4885 |
| US-10640516-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | PIK3CA, MTOR, PIKFYVE | MTOR 2/4885PIK3CA 1/4885PIK3R1 30/4885 |
| US-20230212160-A1 | 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | MTOR 241/4885PIK3CA 108/4885PIK3R1 520/4885 |
| US-20200277304-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | PIK3CA, MTOR, PIKFYVE | MTOR 2/4885PIK3CA 1/4885PIK3R1 30/4885 |
| US-20190031682-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | PIK3CA, MTOR, PIKFYVE | MTOR 2/4885PIK3CA 1/4885PIK3R1 30/4885 |
| US-20190284178-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | CHRM1, CHRM2, C1R | MTOR 4473/4885PIK3CA 4513/4885PIK3R1 3948/4885 |
| US-20190290653-A1 | TREATMENT OF SKIN LESIONS | CXCR3, CCR3, C3AR1 | MTOR 4107/4885PIK3CA 3971/4885PIK3R1 3358/4885 |
| US-11186591-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | PIK3CA, MTOR, PIKFYVE | MTOR 2/4885PIK3CA 1/4885PIK3R1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.